Logo image of MDG1.DE

MEDIGENE AG (MDG1.DE) Stock Fundamental Analysis

FRA:MDG1 - Deutsche Boerse Ag - DE000A40ESG2 - Common Stock - Currency: EUR

0.1335  -0.05 (-27.64%)

Fundamental Rating

2

MDG1 gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. While MDG1 seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, MDG1 is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MDG1 had negative earnings in the past year.
In the past year MDG1 has reported a negative cash flow from operations.
MDG1 had negative earnings in each of the past 5 years.
In the past 5 years MDG1 reported 4 times negative operating cash flow.
MDG1.DE Yearly Net Income VS EBIT VS OCF VS FCFMDG1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

1.2 Ratios

The Return On Assets of MDG1 (-56.15%) is worse than 61.97% of its industry peers.
MDG1's Return On Equity of -82.28% is in line compared to the rest of the industry. MDG1 outperforms 46.48% of its industry peers.
Industry RankSector Rank
ROA -56.15%
ROE -82.28%
ROIC N/A
ROA(3y)-27.97%
ROA(5y)-28.16%
ROE(3y)-40.52%
ROE(5y)-40.06%
ROIC(3y)N/A
ROIC(5y)N/A
MDG1.DE Yearly ROA, ROE, ROICMDG1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

With a decent Gross Margin value of 72.77%, MDG1 is doing good in the industry, outperforming 70.42% of the companies in the same industry.
MDG1's Gross Margin has declined in the last couple of years.
MDG1 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.13%
GM growth 5Y-3.96%
MDG1.DE Yearly Profit, Operating, Gross MarginsMDG1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

MDG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDG1 has about the same amount of shares outstanding.
Compared to 5 years ago, MDG1 has less shares outstanding
Compared to 1 year ago, MDG1 has a worse debt to assets ratio.
MDG1.DE Yearly Shares OutstandingMDG1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
MDG1.DE Yearly Total Debt VS Total AssetsMDG1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -25.08, we must say that MDG1 is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MDG1 (-25.08) is worse than 83.10% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that MDG1 is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.08, MDG1 is doing good in the industry, outperforming 71.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -25.08
ROIC/WACCN/A
WACC7.78%
MDG1.DE Yearly LT Debt VS Equity VS FCFMDG1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

MDG1 has a Current Ratio of 2.39. This indicates that MDG1 is financially healthy and has no problem in meeting its short term obligations.
MDG1 has a Current ratio of 2.39. This is comparable to the rest of the industry: MDG1 outperforms 53.52% of its industry peers.
MDG1 has a Quick Ratio of 2.39. This indicates that MDG1 is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MDG1 (2.39) is better than 60.56% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.39
MDG1.DE Yearly Current Assets VS Current LiabilitesMDG1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for MDG1 have decreased strongly by -94.19% in the last year.
MDG1 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.69%.
The Revenue has been decreasing by -4.89% on average over the past years.
EPS 1Y (TTM)-94.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-91.4%
Revenue 1Y (TTM)-80.69%
Revenue growth 3Y-11.65%
Revenue growth 5Y-4.89%
Sales Q2Q%-6%

3.2 Future

Based on estimates for the next years, MDG1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.04% on average per year.
MDG1 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.49% yearly.
EPS Next Y38.46%
EPS Next 2Y20.82%
EPS Next 3Y18.2%
EPS Next 5Y12.04%
Revenue Next Year100%
Revenue Next 2Y90.69%
Revenue Next 3Y13.3%
Revenue Next 5Y20.49%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDG1.DE Yearly Revenue VS EstimatesMDG1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M
MDG1.DE Yearly EPS VS EstimatesMDG1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MDG1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MDG1 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDG1.DE Price Earnings VS Forward Price EarningsMDG1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDG1.DE Per share dataMDG1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as MDG1's earnings are expected to grow with 18.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.82%
EPS Next 3Y18.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDG1!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIGENE AG

FRA:MDG1 (4/29/2025, 7:00:00 PM)

0.1335

-0.05 (-27.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-24 2025-04-24
Earnings (Next)08-12 2025-08-12
Inst Owners2.38%
Inst Owner ChangeN/A
Ins Owners3.36%
Ins Owner ChangeN/A
Market Cap1.99M
Analysts82.5
Price Target3.88 (2806.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)31.03%
PT rev (3m)31.03%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.2
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.41
BVpS1.32
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.15%
ROE -82.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.77%
FCFM N/A
ROA(3y)-27.97%
ROA(5y)-28.16%
ROE(3y)-40.52%
ROE(5y)-40.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.13%
GM growth 5Y-3.96%
F-Score1
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.34%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.39
Altman-Z -25.08
F-Score1
WACC7.78%
ROIC/WACCN/A
Cap/Depr(3y)17.88%
Cap/Depr(5y)24.26%
Cap/Sales(3y)5.12%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-94.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-91.4%
EPS Next Y38.46%
EPS Next 2Y20.82%
EPS Next 3Y18.2%
EPS Next 5Y12.04%
Revenue 1Y (TTM)-80.69%
Revenue growth 3Y-11.65%
Revenue growth 5Y-4.89%
Sales Q2Q%-6%
Revenue Next Year100%
Revenue Next 2Y90.69%
Revenue Next 3Y13.3%
Revenue Next 5Y20.49%
EBIT growth 1Y-85.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.4%
EBIT Next 3Y12.36%
EBIT Next 5Y9.43%
FCF growth 1Y-262.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-257.03%
OCF growth 3YN/A
OCF growth 5YN/A